Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Recruiting · NCT05308264 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-08-10 | NCT05308264 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rigel Pharmaceuticals | 13 |
15 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Duke Cancer Institute | Durham | United States | 9 |
| Ichan School of Medicine at Mount Sinai | New York | United States | 14 |
| Intermountain Healthcare | Salt Lake City | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Mount Sinai Medical Center | Miami Beach | United States | 116 |
| Oncology Clinical Research Referral Office | Hackensack | United States | 1 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 1 |
| Stanford Cancer Institute | Palo Alto | United States | 21 |
| The Ohio State University Comprehensive Cancer Center | Columbus | United States | 29 |
| University of California, Irvine | Orange | United States | 29 |
| University of California, Los Angeles | Los Angeles | United States | 142 |
| University of Miami | Miami | United States | 327 |
| University of Texas, Southwestern | Dallas | United States | 5 |
| WashU Medicine | St Louis | United States | 3 |